Amy M. Linabery

Amy M. Linabery

Auto-generated profile, based on publicly available information

Amy M. Linabery

Division of Pediatric Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, MN

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2007 in Cancer
Verified
Journal Article
Open access
PDF file
ALAmy M. Linabery
Amy M. Linabery
JRJulie A. Ross
Julie A. Ross
BACKGROUND.: The etiology of most pediatric neoplasms remains elusive. Examination of population‐based incidence data provides insight regarding etiology among various demographic groups and may result in new hypotheses. The objective of the current study was to present updated information regarding childhood cancer incidence and trends in the U.S. overall and among demographic subgroups, including Asian/Pacific Islanders and Hispanics, for whom to the authors' knowledge trends have not been previously examined.METHODS.: Data obtained by 13 registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program were evaluated to assess incidence and trends of common primary cancers diagnosed between 1992 and 2004 among children aged birth to 19 years. Frequencies, age‐adjusted incidence rates, and joinpoint regression results, including annual percent change (APC) in incidence rates (and 95% confidence intervals [95% CI]), were calculated.RESULTS.: Between 1992 and 2004, a modest, nonsignificant increase in the average annual incidence rate (APC, 0.4%; 95% CI, −0.1%–0.8%) was observed for all pediatric cancer diagnoses combined. There was a suggestion of an increase in leukemia (APC, 0.7%; 95% CI, −0.1%–1.5%), and acute lymphoblastic leukemia in particular (APC, 0.8%; 95% CI, −0.4%–1.9%), whereas rates for central nervous system tumors overall were stable (APC, −0.1%; 95% CI, −1.1%–1.0%); 2 joinpoints were observed for astrocytoma. Rate increases were noted for hepatoblastoma (APC, 4.3%; 95% CI, 0.2%–8.7%) and melanoma (APC, 2.8%; 95% CI, 0.5%–5.1%). Differences by demographic group (sex, age, and race/ethnicity) are also described.CONCLUSIONS.: The observed trends reinforce an ongoing need for population‐based surveillance and further etiologic studies. Cancer 2008. © 2007 American Cancer Society.

17 June 2009 in Cancer
Verified
Journal Article
Open access
PDF file
SOSimona Ognjanovic
Simona Ognjanovic
ALAmy M. Linabery
Amy M. Linabery
BCBridget Charbonneau
Bridget Charbonneau
JRJulie A. Ross
Julie A. Ross
BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents aged <20 years; its etiology remains largely unknown. It is believed that embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS), the most common subtypes, arise through distinct biologic mechanisms. The authors of this report evaluated incidence and survival trends by RMS demographic subgroups to inform future etiologic hypotheses.METHODS: Incidence and survival trends in RMS among children and adolescents aged <20 years were analyzed using data from the Surveillance, Epidemiology, and End Results Program. Frequencies, age‐adjusted incidence and survival rates, and joinpoint regression results, including annual percentage change (APC) and 95% confidence interval (CI), were calculated.RESULTS: Between 1975 and 2005, the incidence of ERMS was stable, whereas a significant increase in the incidence of ARMS was observed (APC, 4.20%; 95%CI, 2.60%‐5.82%). This trend may have been attributable in part to shifts in diagnosis, because a significant negative trend in RMS, not otherwise specified was observed concurrently. A bimodal age peak for ERMS was observed, with the second, smaller peak in adolescence noted for males only; ARMS incidence did not vary by age or sex. Five‐year survival rates for RMS and ERMS increased during the period from 1976 to 1980 (52.7% and 60.9%, respectively) to the period from 1996 to 2000 (61.8% and 73.4%, respectively), whereas there was little improvement for ARMS (40.1% and 47.8%, respectively).CONCLUSIONS: Observed differences in incidence and survival for 2 major RMS subtypes across sex and age subgroups further supported the hypothesis that there are unique underlying etiologies for these tumors. Exploration of these differences presents an opportunity to increase current knowledge of RMS. Cancer 2009. © 2009 American Cancer Society.

17 October 2008 in Cancer
Verified
Journal Article
Open access
PDF file
ALAmy M. Linabery
Amy M. Linabery
JRJulie A. Ross
Julie A. Ross
BACKGROUND.: Survival trends provide a measure of improvement in detection and treatment over time. In the current study, updated childhood and adolescent cancer survival statistics are presented, overall and among demographic subgroups, including Hispanics, for whom to the authors' knowledge national rates have not been previously reported. These results extend those provided by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program in their detail and interpretation.METHODS.: Survival trends of primary cancers in children and adolescents (ages birth to 19 years) were evaluated using SEER 9 data. Five‐year and 10‐year relative survival rates across 5‐year (1975‐1979, 1985‐1989, and 1995‐1999) and 10‐year (1975‐1984 and 1985‐1994) cohorts were compared via Z‐tests. Annual percent change (APC) in survival was computed via weighted least‐squares regression. Rates in Hispanic children and adolescents were compared with those in non‐Hispanic whites and blacks (SEER 13, 1995‐1999).RESULTS.: Five‐year survival rates increased significantly overall (1975‐1979: 63% vs 1995‐1999: 79%; P < .0001) and for nearly all histologic types examined; increases were greatest for ependymoma (+37%; P < .0001) and non‐Hodgkin lymphoma (+34%; P < .0001). Hispanic children and adolescents had somewhat poorer 5‐year rates than non‐Hispanic whites overall (74% vs 81%; P < .0001) and for Ewing sarcoma, leukemia, central nervous system tumors, and melanoma. Ten‐year rates also increased significantly overall (1975‐1984: 61% vs 1985‐1994: 72%; P < .0001) and for a majority of cancer types. The largest improvements were noted for acute lymphoblastic leukemia (+19%; P < .0001) and non‐Hodgkin lymphoma (+19%; P < .0001).CONCLUSIONS.: Observed trends reinforce the need for resources devoted to advancing treatment modalities, reducing disparities among racial/ethnic groups and adolescents, and providing long‐term care of survivors. Cancer 2008. © 2008 American Cancer Society.

8 October 2012 in Pediatric Obesity
Verified
Journal Article
Closed access
PDF file
ALA. M. Linabery
A. M. Linabery
RNR. W. Nahhas
R. W. Nahhas
WJW. Johnson
W. Johnson
ACA. C. Choh
A. C. Choh
BTB. Towne
B. Towne
EDE. W. Demerath
E. W. Demerath

12 March 2010 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
ALAmy M. Linabery
Amy M. Linabery
AJAnne M. Jurek
Anne M. Jurek
SDSue Duval
Sue Duval
JRJulie A. Ross
Julie A. Ross
Atopic disease is hypothesized to be protective against several malignancies, including childhood/adolescent leukemia. To summarize the available epidemiologic evidence, the authors performed a meta-analysis of associations between atopy/allergies, asthma, eczema, hay fever, and hives and childhood/adolescent leukemia, acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). They searched MEDLINE literature (1952–March 2009) and queried international experts to identify eligible studies. Ten case-control studies were included. Summary odds ratios and 95% confidence intervals were computed via random-effects models. Odds ratios for atopy/allergies were 1.42 (95% confidence interval (CI): 0.60, 3.35) for 3 studies of leukemia overall, 0.69 (95% CI: 0.54, 0.89) for 6 studies of ALL, and 0.87 (95% CI: 0.62, 1.22) for 2 studies of AML, with high levels of heterogeneity detected for leukemia overall and ALL. Inverse associations were observed for ALL and asthma (odds ratio (OR) = 0.79, 95% CI: 0.61, 1.02), eczema (OR = 0.74, 95% CI: 0.58, 0.96), and hay fever (OR = 0.55, 95% CI: 0.46, 0.66) examined separately. Odds ratios for ALL differed by study design, exposure data source, and latency period, indicating that these factors affect study results. These results should be interpreted cautiously given the modest number of studies, substantial heterogeneity, and potential exposure misclassification but are useful in designing future research.

31 March 2016 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
APAnna Prizment
Anna Prizment
ALAmy M. Linabery
Amy M. Linabery
PLPamela L. Lutsey
Pamela L. Lutsey
ESElizabeth Selvin
Elizabeth Selvin
HNHeather H. Nelson
Heather H. Nelson
CJCorinne Joshu
Corinne Joshu
Background: Serum β-2 microglobulin (B2M), a major histocompatibility complex class I molecule that is a biomarker of kidney filtration and increased cell turnover, is elevated at the time of diagnosis in hematological and some solid cancers. However, serum B2M was not examined prospectively as a marker for cancer risk. We hypothesized that in a population without a prior cancer diagnosis, serum B2M is associated with risk of cancer (n = 2,436), including colorectal (n = 255), lung (n = 298), breast (n = 424), and prostate (n = 524) cancers, and hematological (n = 176) malignancies.Methods: The analytical cohort (n = 12,300) was followed for incident cancers from 1990 through 2006. B2M (range, 0.9–57.8 mg/L) was measured in stored serum collected in 1990–1992. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals for cancer incidence and mortality in relation to quartiles of B2M.Results: Adjusting for age, sex, race, center, education, body mass index, smoking, aspirin, and hormone therapy (in women) and comparing highest to lowest B2M quartiles, HRs were 1.25 (1.06–1.47; Ptrend = 0.002) for total cancer risk and 2.21 (1.32–3.70; Ptrend=0.001) for colorectal cancer risk, with similar HRs for colon and rectal cancers. These associations remained after adjustment for an inflammatory biomarker, C-reactive protein, and after excluding the first three years of follow-up. Significant associations were also observed for mortality from total, lung, and hematological cancers.Conclusions: These findings provide the first evidence that higher serum B2M is associated with increased colorectal cancer risk.Impact: This study supports B2M as a potential biomarker for colorectal cancer risk. Cancer Epidemiol Biomarkers Prev; 25(4); 657–64. ©2016 AACR.